Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor Treatment

• Status: Completed
• Trial end date: 1969-12-31

Summary

The purpose of this study is to see if it is safe and effective to give adefovir dipivoxil plus abacavir (ABC) plus efavirenz (EFV) plus amprenavir (APV) to HIV-infected patients who have failed to respond to previous treatment with protease inhibitors (PIs).

• Phase: Phase 2

Details

• Lead Sponsor: Gilead Sciences
• Collaborators: Dupont Applied Biosciences; Glaxo Wellcome
• Treatments: Abacavir; Adefovir; Adefovir dipivoxil; Amprenavir; Efavirenz; HIV Protease Inhibitors; Protease Inhibitors